Evaluating the real-world safety of cholestyramine for the treatment of hyperlipidemia: disproportionality analysis of FAERS data.

ABSTRACT:

Background

Hypercholesterolemia is a significant risk factor for severe cardiovascular diseases. Cholestyramine lowers serum low-density lipoprotein cholesterol (LDL-C) levels and is clinically indicated for the treatment of primary hypercholesterolemia, relieve itching symptoms caused by bile acid accumulation in cholestatic diseases (such as primary biliary cirrhosis), as well as to manage bile acid diarrhea resulting from bile acid metabolic disorders. With its widespread clinical application, it is essential to understand its safety in real-world settings.

Methods

This study evaluated the clinical safety of cholestyramine by analyzing all adverse event reports since 2004 in the FDA Adverse Event Reporting System (FAERS), where cholestyramine was identified as the primary

SUBMITTER: Li Q 

PROVIDER: S-EPMC12932148 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature